A share price of Fulcrum Therapeutics Inc [FULC] is currently trading at $14.6, up 12.39%. An important factor to consider is whether the stock is rising or falling in short-term value. The FULC shares have gain 63.13% over the last week, with a monthly amount glided 91.35%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on July 29, 2025, and elevated its price target to $12. On May 23, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $12 on the stock. Cantor Fitzgerald upgraded its rating to an Overweight but stick to its price target of $10 on May 15, 2025. H.C. Wainwright downgraded its rating to a Neutral and reduced its price target to $4 on September 13, 2024. Stifel downgraded its rating to Hold for this stock on September 12, 2024. In a note dated September 12, 2024, RBC Capital Mkts downgraded an Sector Perform rating on this stock and revised its target price from $15 to $4.
Fulcrum Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $2.32 and $15.74. Currently, Wall Street analysts expect the stock to reach $20.14 within the next 12 months. Fulcrum Therapeutics Inc [NASDAQ: FULC] shares were valued at $14.6 at the most recent close of the market. An investor can expect a potential return of 37.95% based on the average FULC price forecast.
Analyzing the FULC fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.32 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.68 points at the first support level, and at 10.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.90, and for the 2nd resistance point, it is at 17.21.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Fulcrum Therapeutics Inc [NASDAQ:FULC] is 17.70. On the other hand, the Quick Ratio is 17.70, and the Cash Ratio is 4.05.
Transactions by insiders
Recent insider trading involved RA Capital Healthcare Fund LP, 10% Owner, that happened on Dec 08 ’25 when 4.18 million shares were purchased. Director, Gould Robert J completed a deal on Nov 19 ’25 to sell 15000.0 shares. Meanwhile, Director ROBERT J GOULD bought 45000.0 shares on Nov 19 ’25.
